APLS
Apellis Pharmaceuticals Inc.
$23.49
+$0.48(+2.09%)
65
Overall
40
Value
90
Tech
--
Quality
Market Cap
$3.01B
Volume
1.55M
52W Range
$16.10 - $35.72
Target Price
$37.25
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | -- | -- | -- | $250.6M | $66.6M | $75.4M | $396.6M | $781.4M | ||
| Total Revenue | -- | -- | -- | $250.6M | $66.6M | $75.4M | $396.6M | $781.4M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | -- | -- | -- | $25.1M | $5.2M | $5.6M | $6.4M | $117.7M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | -- | -- | -- | $225.6M | $61.4M | $69.8M | $396.6M | $663.6M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $50.8M | $-127.9M | $288.0M | $464.4M | $602.8M | $664.4M | $913.7M | $946.3M | ||
| Research & Development | $40.3M | $105.3M | $221.0M | $299.9M | $345.9M | $387.2M | $354.4M | $327.6M | ||
| Research Expense | $40.3M | $105.3M | $221.0M | $299.9M | $345.9M | $387.2M | $354.4M | $327.6M | ||
| Selling, General & Administrative | $10.5M | $22.6M | $67.0M | $139.4M | $176.8M | $277.2M | $500.8M | $501.1M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | $86.5M | $83.3M | ||
| General & Administrative Expenses | $10.5M | $22.6M | $67.0M | $139.4M | $176.8M | $277.2M | $500.8M | $501.1M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | -- | $86.5M | $83.3M | ||
| Salaries & Wages | $-5.4M | $-7.7M | -- | -- | -- | $91.1M | $105.9M | $114.1M | ||
| Amortization | -- | -- | $52.0K | -- | -- | $459.0K | $297.0K | -- | ||
| Other Operating Expenses | -- | -- | $2.4M | $-25.1M | $-80.2M | $6.2M | $7.0M | $10.2M | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-50.8M | $-127.9M | $-288.0M | $-213.7M | $-536.3M | $-594.6M | $-517.1M | $-165.0M | ||
| EBITDA | $-50.6M | $-126.8M | $-302.1M | $-312.2M | $-731.3M | $-616.9M | $-524.4M | $-193.4M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $29.9M | $13.2M | $32.6M | $29.6M | -- | ||
| Intinc | $-96.9K | -- | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-96.9K | -- | -- | -- | -- | $23.7M | $8.6M | -- | ||
| Gain on Sale of Securities | $277.8K | $3.0M | $-9.7M | $-98.9M | $-97.3M | $8.9M | $20.9M | $12.8M | ||
| Other Income/Expense | $-135.7K | $-2.9M | $11.4M | $99.4M | $95.9M | $-33.2M | $-20.2M | $-10.6M | ||
| Other Special Charges | $-142.2K | $-25.2K | $-1.7M | $-501.0K | $1.4M | $-288.0K | $-727.0K | $-2.2M | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-50.6M | $-127.5M | $-304.7M | $-313.1M | $-732.8M | $-618.9M | $-526.5M | $-196.7M | ||
| Pre-Tax Income | $-50.6M | $-127.5M | $-304.7M | $-343.0M | $-746.0M | $-651.5M | $-526.5M | $-196.7M | ||
| INCOME TAX | ||||||||||
| Tax Provision | $-50.4K | -- | $-16.4M | $1.8M | $352.0K | $669.0K | $2.1M | $1.2M | ||
| NET INCOME | ||||||||||
| Net Income | $-51.0M | $-127.5M | $-304.7M | $-344.9M | $-746.4M | $-652.2M | $-528.6M | $-197.9M | ||
| Net Income (Continuing Operations) | $-51.0M | $-127.5M | $-304.7M | $-344.9M | $-746.4M | $-652.2M | $-528.6M | $-197.9M | ||
| Net Income (Discontinued Operations) | $-51.0M | $-127.5M | $-304.7M | $-344.9M | $-746.4M | $-652.2M | $-528.6M | $-197.9M | ||
| Net Income (Common Stockholders) | $-51.0M | $-127.5M | $-299.4M | $-344.9M | $-746.4M | $-652.2M | $-440.5M | $-197.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-194.7M | ||
| TOTALS | ||||||||||
| Total Expenses | $50.8M | $-127.9M | $288.0M | $464.4M | $602.8M | $670.0M | $920.1M | $965.3M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $13.9M | $54.4M | $62.2M | $75.2M | $84.4M | $106.1M | $118.7M | $123.9M | ||
| Average Shares Outstanding (Diluted) | $13.9M | $54.5M | $62.2M | $75.2M | -- | $106.1M | $118.7M | $123.9M | ||
| Shares Outstanding | $50.4M | $56.3M | $75.3M | $80.4M | $97.7M | $126.3M | $120.6M | $125.5M | ||
| Basic EPS | -- | -- | $-4.9 | $-4.59 | $-8.84 | $-6.15 | $-4.45 | $-1.6 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-4.9 | $-4.59 | $-8.84 | $-6.15 | $-4.45 | $-1.6 | ||
| Diluted EPS | $-3.68 | $-2.34 | $-4.9 | $-4.59 | $-8.84 | $-6.15 | $-4.45 | $-1.6 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-6.15 | $-4.45 | $-1.6 | ||
| OTHER METRICS | ||||||||||
| Net Income From Other Gains Losses | $-374.7K | $-2.5M | $-5.3M | -- | -- | -- | -- | -- | ||
| Other Gand A | $10.5M | $22.6M | $67.0M | $139.4M | $176.8M | $277.2M | $500.8M | $501.1M | ||
| Rent And Landing Fees | $10.5M | $22.6M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | APLS | $23.49 | +2.1% | 1.55M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Apellis Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW